Kwality Pharma: Profit **69%** Bhaga! Lekin Receivables Ka Tension?

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorRiya Kapoor|Published at:
Kwality Pharma: Profit **69%** Bhaga! Lekin Receivables Ka Tension?
Overview

Arre bhaiyon aur behenon, Kwality Pharma ke investors ke liye ek mast khabar hai! Company ne FY26 mein jabardast performance dikhaya hai, net profit **69%** se badh gaya hai aur revenue bhi **36%** upar chala gaya. Rating agency ICRA ne bhi company ki credit rating ko upgrade kiya hai. Lekin ek bada issue hai, woh hai unke receivables aur paisa collect karne mein lagta time. Isse liquidity par thoda tension hai.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Company ne FY26 ke liye shaandar results announce kiye hain. Consolidated net profit 69.20% bhadkaar ₹6,734.60 lakhs yaani ki lagbhag ₹67.35 Crore ho gaya. Revenue bhi 35.96% badha aur ₹50,594.19 lakhs yaani ₹505.94 Crore tak pahunch gaya. Sirf FY26 hi nahi, Q4 mein bhi performance accha raha, net profit ₹2,531.05 lakhs (₹25.31 Cr) aur revenue ₹15,817.17 lakhs (₹158.17 Cr) tha.

Iske alawa, credit rating agency ICRA ne company ki credit rating ko BBB+ par upgrade kar diya hai, jo pehle B+ thi. Auditors ne bhi financial statements par koi badi kami nahi paayi. Yeh sab growth aur acchi financial health ke signs hain, jo investors ko pasand aayenge aur company ke liye paisa uthana bhi aasan ho sakta hai.

Lekin, bhaiyon, ek bada twist hai! Company ke total assets ka 47.29% hissa yaani ₹28,005.24 lakhs (₹280.05 Crore) sirf trade receivables mein atka hua hai. Aur kya batayein, debtor days 208 din ho gaye hain! Matlab, customers se paise collect karne mein itna time lag raha hai ki company ki liquidity par serious risk aa sakta hai. Agar logo ne time par payment nahi kiya toh company ke rozmarra ke operations mein cash ki kami ho sakti hai.

Yeh receivables aur liquidity ka issue pharma sector mein kaafi common hai, jab companies aggressive sales strategy follow karti hain. Ab investors ki nazar management par rahegi ki woh isko kaise manage karte hain aur kitni jaldi paisa collect karte hain. Q1 FY27 mein debtor days ka trend aur collection efficiency dekhna important hoga.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.